DISCLAIMER: This page is intended for members of the general public in Poland only.
The information provided on this site is intended for general information and education for Poland-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Important information
For more information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601), download the Package Leaflet.
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Poland.
Departament Monitorowania Niepożądanych Działań Produktów Leczniczych Urzędu Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych
Al. Jerozolimskie 181C
02-222 Warszawa, Polska
Tel.: +48 22 49 21 301
Faks: +48 22 49 21 309
Strona internetowa: www.smz.ezdrowie.gov.pl
Contact Us
Tel: +48 22 104 74 91
09:00 - 17:00
Monday - Friday